Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Ligand-based Targeted Therapy: A Novel Strategy For Hepatocellular Carcinoma

M. Li, W. Zhang, Birong Wang, Y. Gao, Z. Song, Q. Zheng
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide. Chemotherapy is recommended to patients with intermediate or advanced stage cancer. However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concentration in cancer cells, and so on. Nanoparticle-mediated targeted drug delivery system can surmount the aforementioned obstacles through enhanced permeability and retention effect and active targeting as a novel approach of therapeutics for HCC in recent years. The active targeting is triggered by ligands on the delivery system, which recognize with and internalize into hepatoma cells with high specificity and efficiency. This review focuses on the latest targeted delivery systems for HCC and summarizes the ligands that can enhance the capacity of active targeting, to provide some insight into future research in nanomedicine for HCC.
This paper references
10.1016/j.biomaterials.2012.09.027
Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery.
Tianyue Jiang (2012)
10.1016/0005-2736(91)90253-5
Specific binding of glycyrrhetinic acid to the rat liver membrane.
M. Negishi (1991)
10.1111/j.1478-3231.2006.01316.x
Expression of iron regulatory genes in a rat model of hepatocellular carcinoma
P. Holmström (2006)
10.1016/J.CANLET.2005.01.024
Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer.
J. Chen (2006)
10.1158/0008-5472.CAN-06-1501
Cancer's molecular sweet tooth and the Warburg effect.
J. Kim (2006)
Antibodyconjugated nanoparticles for biomedical applications
M Arruebo (2009)
10.1038/nrgastro.2013.143
Chemopreventive strategies in hepatocellular carcinoma
S. Singh (2014)
10.1016/j.biomaterials.2011.02.029
Advantages of RGD peptides for directing cell association with biomaterials.
S. Bellis (2011)
10.1158/1541-7786.MCR-06-0286
HAb18G/CD147 Functions in Invasion and Metastasis of Hepatocellular Carcinoma
J. Xu (2007)
10.1021/mp100185f
Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Liang Han (2010)
10.2217/nnm.10.27
Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation.
W. Wei (2010)
Transferrin targeted core - shell
GL Malarvizhi
10.3892/OL.2015.3242
Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy.
Liyu Chen (2015)
10.7150/jca.7093
A Target-Specific Oral Formulation of Doxorubicin-Protein Nanoparticles: Efficacy and Safety in Hepatocellular Cancer
Kishore Golla (2013)
10.1006/frne.1999.0183
Somatostatin and Its Receptor Family
Y. Patel (1999)
10.1155/2013/917296
The Cell Surface GRP78 Facilitates the Invasion of Hepatocellular Carcinoma Cells
Xiu-Xiu Zhang (2013)
10.1016/j.msec.2012.12.009
Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation.
J. Viota (2013)
10.1053/j.gastro.2015.10.008
Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats.
Xiaodong Wen (2016)
10.1021/acs.molpharmaceut.5b00132
Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.
H. Hanaoka (2015)
10.1182/BLOOD.V84.5.1628.BLOODJOURNAL8451628
Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid.
J. C. Vera (1994)
10.1208/s12249-007-9007-7
Development and Characterization of Pectinate Micro/Nanoparticles for Gene Delivery
P. Opanasopit (2007)
10.1124/mol.115.101360
A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy
J. Gillet (2016)
10.2147/IJN.S59799
N-Succinyl-chitosan nanoparticles coupled with low-density lipoprotein for targeted osthole-loaded delivery to low-density lipoprotein receptor-rich tumors
C. Zhang (2014)
10.1021/acs.molpharmaceut.5b00677
Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
Yuee Cai (2016)
10.1016/S0378-5173(01)00847-X
Biotinylated methotrexate loaded erythrocytes for enhanced liver uptake. 'A study on the rat'.
P. R. Mishra (2002)
10.1016/j.ijpharm.2014.07.036
Smart magnetic nanoparticle-aptamer probe for targeted imaging and treatment of hepatocellular carcinoma.
C. Pilapong (2014)
10.1371/journal.pone.0136673
A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy
T. Trinh (2015)
10.1002/JPS.20443
Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes.
Chittima Managit (2005)
10.1155/2016/2862738
Porous Lactose-Modified Chitosan Scaffold for Liver Tissue Engineering: Influence of Galactose Moieties on Cell Attachment and Mechanical Stability
Birong Wang (2016)
10.1016/j.biomaterials.2014.05.058
Intracellular redox-activated anticancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity.
Z. Luo (2014)
10.1016/j.jconrel.2011.03.012
Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.
Golam Kibria (2011)
10.1016/j.ijpharm.2014.10.041
Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
O. Mezghrani (2015)
10.1096/fj.05-4058com
Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics
Z. Li (2005)
10.1016/j.biomaterials.2010.03.066
Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
L. Fan (2010)
10.1016/S0304-3835(98)00222-5
Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters.
T. Tengchaisri (1998)
10.1007/s00432-009-0585-5
Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications
Hsi-Huang Tseng (2009)
10.1016/j.biomaterials.2013.02.018
Recognition and capture of metastatic hepatocellular carcinoma cells using aptamer-conjugated quantum dots and magnetic particles.
Fubing Wang (2013)
10.1039/c4cc02767a
Targeted and image-guided photodynamic cancer therapy based on organic nanoparticles with aggregation-induced emission characteristics.
Y. Yuan (2014)
10.1016/j.biomaterials.2012.02.045
A gene nanocomplex conjugated with monoclonal antibodies for targeted therapy of hepatocellular carcinoma.
Jun-Juan Wang (2012)
10.1021/bm401749t
Glyco-nanoparticles with sheddable saccharide shells: a unique and potent platform for hepatoma-targeting delivery of anticancer drugs.
Wei Chen (2014)
10.3978/J.ISSN.2218-676X.2013.10.01
Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules.
J. A. Gutierrez (2013)
10.1016/j.biomaterials.2008.11.027
Galactosylated fluorescent labeled micelles as a liver targeting drug carrier.
De-Qun Wu (2009)
Adenosine A(2b) receptor is highly expressed in human hepatocellular carcinoma.
H. Xiang (2006)
10.1021/bm5009348
Self-regulated multifunctional collaboration of targeted nanocarriers for enhanced tumor therapy.
H. Gao (2014)
10.1016/j.bbrc.2008.06.126
Development of SM5-1-conjugated ultrasmall superparamagnetic iron oxide nanoparticles for hepatoma detection.
Geng Kou (2008)
10.3748/WJG.14.4300
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.
A. Gomaa (2008)
10.1016/J.JTBI.2005.12.022
Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies.
S. McDougall (2006)
10.1021/acs.biomac.5b00906
Asialoglycoprotein Receptor-Mediated Gene Delivery to Hepatocytes Using Galactosylated Polymers.
Bindu Thapa (2015)
10.1111/j.1440-1681.2007.04593.x
siRNA‐MEDIATED BCL‐2 AND BCL‐XL GENE SILENCING SENSITIZES HUMAN HEPATOBLASTOMA CELLS TO CHEMOTHERAPEUTIC DRUGS
X. Lei (2007)
10.1002/jbm.a.34493
A dual-functionally modified chitosan derivative for efficient liver-targeted gene delivery.
B. Xiao (2013)
10.1016/j.colsurfb.2013.04.022
Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells.
R. Villa (2013)
10.3109/03639045.2016.1173052
Novel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors
Ahmed A H Abdellatif (2016)
10.1038/mt.2010.296
Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.
K. Klutz (2011)
Identification of FGF receptorbinding peptides for cancer gene therapy
F Maruta (2002)
10.1002/HEP.1840090419
In Vivo expression of two novel tumor‐associated antigens and their use in immunolocalization of human hepatocellular carcinoma
H. Takahashi (1989)
10.1038/NATREVMATS.2016.14
Analysis of nanoparticle delivery to tumours
Stefan Wilhelm (2016)
10.1016/j.ijbiomac.2016.03.040
Dextran based nanosized carrier for the controlled and targeted delivery of curcumin to liver cancer cells.
T. Anirudhan (2016)
10.1016/j.addr.2008.08.005
Active targeting schemes for nanoparticle systems in cancer therapeutics.
J. D. Byrne (2008)
10.1016/j.ijpharm.2014.04.008
Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Ling Mei (2014)
10.1002/JCTB.4555
Monoclonal antibody‐targeted polymeric nanoparticles for cancer therapy – future prospects
S. Goodall (2015)
10.1016/j.nano.2016.01.017
iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
J. Zhang (2016)
The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma
Z Xu (2010)
10.1002/hep.28409
Theranostical nanosystem‐mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma
Y. Guo (2016)
10.1007/s00232-014-9637-0
Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy
Stephanie M. Tortorella (2014)
10.1016/j.jconrel.2014.05.016
Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice.
Y. Zou (2014)
10.1002/hep.23441
Serotonin promotes tumor growth in human hepatocellular cancer
C. Soll (2010)
10.1016/j.nano.2011.05.016
Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging.
S. Parveen (2012)
10.1073/pnas.1217868110
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma
M. Feng (2013)
10.1016/j.cell.2007.02.050
Opposing Effects of Retinoic Acid on Cell Growth Result from Alternate Activation of Two Different Nuclear Receptors
T. Schug (2007)
10.1016/j.biomaterials.2008.09.014
The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.
Zhenghong Xu (2009)
10.2147/IJN.S45767
Acid-triggered core cross-linked nanomicelles for targeted drug delivery and magnetic resonance imaging in liver cancer cells
X. Li (2013)
10.1016/j.biomaterials.2010.02.068
Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer.
Jin Hee Maeng (2010)
10.1007/s00249-008-0368-y
Molecular structure of low density lipoprotein: current status and future challenges
R. Prassl (2008)
10.1530/ERC-13-0283
Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.
W. Ma (2014)
10.1002/HEP.1840220528
Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro
D. Moradpour (1995)
10.1016/j.jphotobiol.2014.07.005
Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer.
J. Chang (2014)
10.1016/j.jconrel.2010.08.027
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
F. Danhier (2010)
10.1002/smll.201300171
Bright far-red/near-infrared conjugated polymer nanoparticles for in vivo bioimaging.
D. Ding (2013)
10.1111/J.1432-0436.2007.00238.X
The epidermal growth factor receptor: from development to tumorigenesis.
M. Sibilia (2007)
10.1016/J.JINORGBIO.2004.07.009
Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours.
G. Russell-Jones (2004)
for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma
T Zhou (2014)
10.1093/ANNONC/MDS225
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
C. Verslype (2012)
10.1039/c5cc07818k
Multifunctional organic nanoparticles with aggregation-induced emission (AIE) characteristics for targeted photodynamic therapy and RNA interference therapy.
Guorui Jin (2016)
10.1371/journal.pone.0033434
Targeted Delivery of Chemotherapy Agents Using a Liver Cancer-Specific Aptamer
Ling Meng (2012)
10.1007/BF00253110
Daunorubicin-DNA and doxorubicin-DNA a review of experimental and clinical data
A. Trouet (2004)
10.1053/JHEP.2002.36372
Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice
M. Wolschek (2002)
10.1016/J.BIOMATERIALS.2003.10.063
Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier.
T. Kim (2004)
10.1073/PNAS.83.16.5983
Receptor-mediated folate accumulation is regulated by the cellular folate content.
B. Kamen (1986)
10.1016/j.carbpol.2016.06.024
Lactobionic acid and carboxymethyl chitosan functionalized graphene oxide nanocomposites as targeted anticancer drug delivery systems.
Qixia Pan (2016)
10.1016/j.jconrel.2012.06.019
Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
K. Takara (2012)
10.1016/j.msec.2014.09.038
Glycosaminoglycan-targeted iron oxide nanoparticles for magnetic resonance imaging of liver carcinoma.
Rui-meng Yang (2014)
10.1002/ijc.10966
Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid
M. Jinushi (2003)
10.1021/acsami.5b02261
Improving the Anticancer Efficacy of Laminin Receptor-Specific Therapeutic Ruthenium Nanoparticles (RuBB-Loaded EGCG-RuNPs) via ROS-Dependent Apoptosis in SMMC-7721 Cells.
Yanhui Zhou (2016)
Mol Pharm
(2015)
10.1073/PNAS.0601755103
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
O. Farokhzad (2006)
10.1158/1535-7163.MCT-07-2359
Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery
Albert Lo (2008)
10.1517/17425247.2016.1112374
Recent developments in hyaluronic acid-based nanomedicine for targeted cancer treatment
N. V. Rao (2016)
10.1038/srep22149
Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma
Wan-Jiang Xue (2016)
Galactosylated poly(2-(2aminoethyoxy)ethoxy)phosphazene/DNA complex nanoparticles: in vitro and in vivo evaluation for gene delivery. Biomacromolecules
Y Yang (2010)
10.1016/j.biomaterials.2009.12.019
Lactose mediated liver-targeting effect observed by ex vivo imaging technology.
Ping'an Ma (2010)
10.1021/bm201270m
Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin.
Cunxian Duan (2011)
10.1016/j.semcdb.2014.01.011
Epidermal growth factor, from gene organization to bedside.
F. Zeng (2014)
10.1016/j.biomaterials.2009.09.103
The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model.
Zhenghong Xu (2010)
10.1155/2013/254127
Retinoic acid decorated albumin-chitosan nanoparticles for targeted delivery of doxorubicin hydrochloride in hepatocellular carcinoma
J. Varshosaz (2013)
10.2147/ijn
科技期刊稿件处理的精细化管理——《International Journal of Nanomedicine〉〉投稿体会
鲁翠涛 (2014)
10.1039/b904665h
Aggregation-induced emission: phenomenon, mechanism and applications.
Yuning Hong (2009)
10.1158/1078-0432.CCR-07-1441
Therapeutic Nanoparticles for Drug Delivery in Cancer
Kwangjae Cho (2008)
10.1016/j.biomaterials.2012.02.033
A review of glycosylated carriers for drug delivery.
K. Jain (2012)
10.1136/gut.12.9.756
European Association for the Study of the Liver
M. Dumont (1971)
10.1002/adma.201104066
Design of multifunctional micelle for tumor-targeted intracellular drug release and fluorescent imaging.
W. Wang (2012)
10.1021/am502282f
Dual-modal MRI contrast agent with aggregation-induced emission characteristic for liver specific imaging with long circulation lifetime.
Y. Chen (2014)
10.3109/10717544.2012.739214
Pectin nanoparticle enhances cytotoxicity of methotrexate against hepG2 cells
Chuda Chittasupho (2013)
10.1021/mp800177f
A combined chemoimmunotherapy approach using a plasmid-doxorubicin complex.
Vaishali Bagalkot (2009)
10.1016/j.ijpharm.2011.08.004
Targeted liposomes to deliver DNA to cells expressing 5-HT receptors.
V. Gopal (2011)
10.1016/j.jconrel.2016.02.030
Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma.
Cong Zhang (2016)
10.1016/s0021-9258(18)33240-x
Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features.
Y. Lee (1983)
10.1016/S0168-8278(05)80243-0
MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis.
X. Chenivesse (1993)
10.3748/wjg.v21.i42.12022
Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
J. Varshosaz (2015)
10.1016/j.nano.2015.07.015
Design considerations for nanotherapeutics in oncology.
T. Stylianopoulos (2015)
10.3390/nu7075230
Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome
Samuel Legeay (2015)
10.1007/S00018-005-5368-9
Molecular structure, binding properties and dynamics of lactoferrin.
E. Baker (2005)
10.1016/J.JCONREL.2005.09.001
Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine-graft-poly(ethylene glycol): in vitro and in vivo studies.
E. Kim (2005)
10.1158/0008-5472.CAN-07-1077
Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70.
P. Phillips (2007)
10.1016/S0304-4157(96)00014-7
The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells.
D. Richardson (1997)
10.2147/IJN.S74868
Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78
L. Zhao (2015)
10.1021/bm501066m
Developing genetically engineered encapsulin protein cage nanoparticles as a targeted delivery nanoplatform.
H. Moon (2014)
10.1172/JCI13712
Glypicans: proteoglycans with a surprise.
J. Filmus (2001)
10.1152/AJPRENAL.00171.2004
Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability.
D. Venturoli (2005)
10.1007/s10856-009-3925-8
Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma
Peifeng Liu (2010)
10.1021/bc300015f
Development of human hepatocellular carcinoma cell-targeted protein cages.
R. Toita (2012)
10.1016/j.biomaterials.2010.12.031
Enhancement of cell recognition in vitro by dual-ligand cancer targeting gold nanoparticles.
X. Li (2011)
10.1371/journal.pone.0007240
An Efficient Targeted Drug Delivery through Apotransferrin Loaded Nanoparticles
A. D. Krishna (2009)
Cancer Res
(2002)
Hepatol Res
(2006)
10.1016/j.nano.2015.12.381
Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
X. Zhang (2016)
10.1016/j.bios.2015.08.056
Sensitive electrochemical aptamer cytosensor for highly specific detection of cancer cells based on the hybrid nanoelectrocatalysts and enzyme for signal amplification.
Duanping Sun (2016)
10.1016/j.ijpharm.2015.04.028
Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Y. Li (2015)
10.1016/j.biomaterials.2010.11.061
The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Nuo Cao (2011)
10.1007/978-3-319-08084-0_1
Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors
Jaydev Upponi (2014)
10.1016/j.actbio.2016.01.039
Self-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy.
L. Li (2016)
10.1002/smll.201403073
Aptamers and their applications in nanomedicine.
Hongguang Sun (2015)
10.1016/S0378-5173(99)00447-0
Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system.
U. Gaur (2000)
10.1016/j.jconrel.2013.06.006
Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Xin Li (2013)
10.21037/6391
Emerging roles of FGF signaling in hepatocellular carcinoma.
Nana Zheng (2016)
10.1021/mp5001718
Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor.
H. Tang (2014)
10.1016/j.addr.2012.07.013
Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery.
Marina G. Damiano (2013)
10.1016/j.biomaterials.2012.03.067
CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma.
L. Wang (2012)
10.3748/wjg.v18.i21.2704
GABA stimulates human hepatocellular carcinoma growth through overexpressed GABAA receptor theta subunit.
Yuehui Li (2012)
10.1016/j.addr.2013.08.012
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
R. van der Meel (2013)
10.1016/j.biomaterials.2012.08.057
A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Y. Ding (2012)
10.1177/153537020623100503
Choline Transport for Phospholipid Synthesis
Vera Michel (2006)
10.2174/156720108785915069
Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development.
Y. Li (2008)
10.1016/j.canlet.2016.01.017
Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
L. Shi (2016)
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.
A. Kiss (1997)
10.1021/am504849x
Multifunctional lactobionic acid-modified dendrimers for targeted drug delivery to liver cancer cells: investigating the role played by PEG spacer.
Fanfan Fu (2014)
10.1056/NEJMc081780
Sorafenib in advanced hepatocellular carcinoma.
G. Spinzi (2008)
10.1038/nbt1340
Renal clearance of quantum dots
H. Choi (2007)
10.1016/S0016-5085(03)00689-9
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
M. Capurro (2003)
10.1159/000104457
Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics
Rachel E Airley (2007)
10.3748/wjg.v19.i47.9104
131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma.
Q. He (2013)
10.1161/ATVBAHA.108.179564
The LDL receptor.
J. Goldstein (2009)
10.1186/1477-7819-12-231
Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study
Y. Chun (2014)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1210/EDRV-13-1-18
Molecular and biological properties of the vascular endothelial growth factor family of proteins.
N. Ferrara (1992)
10.1016/j.ccr.2009.10.013
Tissue-penetrating delivery of compounds and nanoparticles into tumors.
K. Sugahara (2009)
10.1021/mp400412c
In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy.
Cui-Yun Yu (2014)
10.1021/am500761x
Lactobionic acid-modified dendrimer-entrapped gold nanoparticles for targeted computed tomography imaging of human hepatocellular carcinoma.
H. Liu (2014)
10.1136/gut.2003.036053
Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma
H. Reynaert (2004)
10.1016/j.ijpharm.2014.02.047
Galactosylated polymeric carriers for liver targeting of sorafenib.
E. Craparo (2014)
Prostaglandin E2 stimulates beta1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/ NF-kappaB pathway. Sci Rep
X Bai (2014)
10.1039/c1cs15113d
Aggregation-induced emission.
Yuning Hong (2011)
10.1021/bm901346m
Galactosylated poly(2-(2-aminoethyoxy)ethoxy)phosphazene/DNA complex nanoparticles: in vitro and in vivo evaluation for gene delivery.
Y. Yang (2010)
10.1016/j.addr.2009.03.007
Magnetic nanoparticles for theragnostics.
V. Shubayev (2009)
10.1021/bm1005992
Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma.
C. Jin (2010)
10.1158/0008-5472.CAN-12-3824
Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.
Hamza Chettouh (2013)
10.1007/s00018-007-7377-3
Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives
M. Lesurtel (2007)
10.1016/S0065-2571(00)00013-3
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
H. Maeda (2001)
10.1016/S0140-6736(00)02654-4
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial
T. Takayama (2000)
10.1038/nm843
Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning
Q. Ye (2003)
10.3748/WJG.V7.I4.445
Hepatocellular carcinoma--cause, treatment and metastasis.
Z. Tang (2001)
The Gerbich blood group system: a review.
P. Walker (2010)
10.1007/s11095-011-0603-6
Liver Cancer Targeting of Doxorubicin with Reduced Distribution to the Heart Using Hematoporphyrin-Modified Albumin Nanoparticles in Rats
J. Chang (2011)
10.1016/j.nano.2011.05.013
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.
L. M. Kaminskas (2012)
10.1021/BC0502107
Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system against cultured HepG2 cells.
Hsiang-Fa Liang (2006)
10.5483/BMBREP.2007.40.5.731
Preparation and Characterization of Paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody.
Geng Kou (2007)
10.1021/bm2006856
Galactose-decorated cross-linked biodegradable poly(ethylene glycol)-b-poly(ε-caprolactone) block copolymer micelles for enhanced hepatoma-targeting delivery of paclitaxel.
R. Yang (2011)
10.1002/smll.201501985
Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.
K. Wang (2016)
10.1016/0026-2862(86)90018-X
Microvascular permeability of normal and neoplastic tissues.
L. E. Gerlowski (1986)
10.1002/JCB.240230111
Sorting and recycling of cell surface receptors and endocytosed ligands: The asialoglycoprotein and transferrin receptors
A. Ciechanover (1983)
10.3389/fonc.2013.00222
Tumor Targeting via Integrin Ligands
U. K. Marelli (2013)
Plasmid pORFhTRAIL and doxorubicin co-delivery targeting to tumor using peptideconjugated polyamidoamine dendrimer
L Han (2011)
10.1158/0008-5472.CAN-15-0977
Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis.
Long-yun Ye (2016)
10.21037/1863
Beyond chemotherapy: systemic treatment options for hepatocellular carcinoma
Zheng Topp (2013)
High density lipoprotein complexes as delivery vehicles for anticancer drugs.
A. Lacko (2002)
10.1007/s00280-006-0393-4
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang (2006)
10.1136/gut.43.6.837
Differential expression of laminin receptors in human hepatocellular carcinoma
I. Ozaki (1998)
10.1158/0008-5472.CAN-08-1973
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Takahiro Ishiguro (2008)
10.1021/ac400366b
Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture.
Yanling Song (2013)
Human hepatic lectin. Physiochemical properties and specificity.
J. Baenziger (1980)
10.1016/0163-7258(93)90009-3
Somatostatin analogs for diagnosis and treatment of cancer.
G. Weckbecker (1993)
10.1007/s10856-011-4494-1
Design and synthesis of dual-ligand modified chitosan as a liver targeting vector
Houxiang Chen (2011)
10.1007/s00262-007-0321-4
Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome
H. Wang (2007)
10.1016/J.IJPHARM.2005.05.020
Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells.
Chittima Managit (2005)
10.1038/srep17904
CD147 monoclonal antibody mediated by chitosan nanoparticles loaded with α-hederin enhances antineoplastic activity and cellular uptake in liver cancer cells
Rong Zhu (2015)
10.1021/acs.bioconjchem.5b00254
Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC).
Devaraja Rajasekaran (2015)
10.2147/IJN.S79598
Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes
Wendian Zhang (2015)
10.1016/j.yexcr.2014.04.005
Therapeutic efficacy of improved α-fetoprotein promoter-mediated tBid delivered by folate-PEI600-cyclodextrin nanopolymer vector in hepatocellular carcinoma.
Bao-guang Hu (2014)
10.1016/J.BBRC.2007.04.039
Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody.
Bohua Li (2007)
10.2174/157488708783330549
Immunotherapy of HCC.
T. Greten (2008)
10.4161/mabs.20933
High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening
Yen Phung (2012)
10.1155/2012/989235
FGF Receptor-Mediated Gene Delivery Using Ligands Coupled to PEI-β-CyD
Yiping Hu (2012)
10.1016/S0169-409X(02)00044-3
Nanoparticles in cancer therapy and diagnosis.
I. Brigger (2002)
10.1517/17425247.2013.837447
Delivery of therapeutic nucleic acids via transferrin and transferrin receptors: lipoplexes and other carriers
C. Tros de Ilarduya (2013)
10.1016/j.biomaterials.2010.09.070
Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer.
Liang Han (2011)
10.1021/bm5003009
Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
Yinan Zhong (2014)
10.1021/BC049971K
A new triantennary galactose-targeted PEGylated gene carrier, characterization of its complex with DNA, and transfection of hepatoma cells.
Benoit Frisch (2004)
10.1016/j.addr.2013.11.009
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
N. Bertrand (2014)
Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo.
S. Zitzmann (2002)
10.1016/j.jconrel.2014.06.038
Insight into nanoparticle cellular uptake and intracellular targeting.
Basit Yameen (2014)
10.1016/j.biomaterials.2014.03.088
Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
Qiao-ling Zhu (2014)
Ligand-based targeted therapy for hepatocellular carcinoma
10.1038/nbt.3330
Principles of nanoparticle design for overcoming biological barriers to drug delivery
E. Blanco (2015)
10.1016/j.biomaterials.2011.08.072
The effect of hydrophilic chain length and iRGD on drug delivery from poly(ε-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles.
Zhenshu Zhu (2011)
10.1016/j.bbrc.2008.11.033
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
K. Nakano (2009)
10.1158/1535-7163.MCT-08-0514
Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments
Jie Gao (2008)
10.1016/j.addr.2011.04.002
Role of tumor vascular architecture in drug delivery.
A. Narang (2011)
10.1016/j.bbcan.2012.02.001
Glucose regulated protein 78: a critical link between tumor microenvironment and cancer hallmarks.
Z. Li (2012)
10.1111/j.1365-2818.2005.01471.x
Porphyrin‐related photosensitizers for cancer imaging and therapeutic applications
K. Berg (2005)
10.3390/toxins2061445
Heat-Labile Enterotoxin: Beyond GM1 Binding
Benjamin Mudrak (2010)
10.1002/(SICI)1096-9896(199605)179:1<74::AID-PATH531>3.0.CO;2-E
CD44 IS EXPRESSED IN HEPATOCELLULAR CARCINOMAS SHOWING VASCULAR INVASION
J. Mathew (1996)
10.1006/MGME.2000.3027
Folic acid: nutritional biochemistry, molecular biology, and role in disease processes.
M. Lucock (2000)
10.1158/0008-5472.CAN-04-1443
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
S. Wilhelm (2004)
10.1002/JPS.10397
Amphiphilic block copolymers for drug delivery.
M. Adams (2003)
10.1007/s10856-013-4895-4
Cross-linked hyaluronic acid sub-micron particles: in vitro and in vivo biodistribution study in cancer xenograft model
F. Rosso (2013)
10.1016/j.jhep.2011.12.001
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
J. Llovet (2012)
10.1038/nrd2614
Nanoparticle therapeutics: an emerging treatment modality for cancer
M. Davis (2008)
Immunotherapy of HCC. Rev Recent Clin Trials
Tf Greten (2008)
10.1016/j.jconrel.2015.02.022
Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications.
A. D’souza (2015)
10.1021/NN502074X
pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma.
Daishun Ling (2014)
10.2217/nnm.15.106
iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells.
Xiao-li Mao (2015)
10.1016/j.canlet.2008.08.031
Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide.
S. Oh (2009)
10.1016/j.carbpol.2015.04.010
Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells).
C. Senthil Kumar (2015)
10.1002/hep.24199
Management of hepatocellular carcinoma: An update
J. Bruix (2011)
10.1016/j.actbio.2015.11.031
Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer.
D. Zhu (2016)
10.1021/acs.biomac.5b00576
Galactose-based Thermosensitive Nanogels for Targeted Drug Delivery of Iodoazomycin Arabinofuranoside (IAZA) for Theranostic Management of Hypoxic Hepatocellular Carcinoma.
Stephen Quan (2015)
10.1039/C2TB00155A
Biotin-decorated fluorescent silica nanoparticles with aggregation-induced emission characteristics: fabrication, cytotoxicity and biological applications.
M. Li (2013)
10.3748/WJG.V13.I3.414
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma.
K. Uka (2007)
iRGD decorated lipidpolymer hybrid nanoparticles for targeted codelivery of doxorubicin and sorafenib to enhance antihepatocellular carcinoma efficacy
J Zhang (2016)
10.1074/jbc.272.30.18982
Glucose Transporter Isoforms GLUT1 and GLUT3 Transport Dehydroascorbic Acid*
S. Rumsey (1997)
10.1016/j.biomaterials.2016.02.007
Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation.
Xibo Ma (2016)
10.1016/j.nano.2014.05.011
Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
G. L. Malarvizhi (2014)
10.2217/nnm.15.43
The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.
Jianxin Jiang (2015)
10.1016/S1359-6446(00)01594-4
Folate-mediated targeting: from diagnostics to drug and gene delivery.
C. P. Leamon (2001)
10.1038/74651
Mechanisms of angiogenesis and arteriogenesis
P. Carmeliet (2000)
Asialoglycoprotein receptormediated gene delivery to hepatocytes using galactosylated polymers. Biomacromolecules
B Thapa (2015)
10.1021/mp100463n
Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Zhigui Su (2011)
Fibroblast growth factors are required for efficient tumor angiogenesis.
A. Compagni (2000)
10.1158/1535-7163.MCT-07-0022
Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator–activated receptor γ agonists in colon cancer cells
Sudhakar Chintharlapalli (2007)
10.1016/j.biomaterials.2012.06.048
Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells.
X. Zhang (2012)
10.1039/c5nr04831a
Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy.
B. Xiao (2015)
10.1021/bm401098w
Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
Yinan Zhong (2013)
10.1016/S0928-0987(02)00257-9
Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system.
K. Na (2003)
10.1158/1078-0432.CCR-11-1813
Expression of Serotonin Receptors in Human Hepatocellular Cancer
C. Soll (2012)
10.2147/IJN.S60764
Preparation of biocompatible heat-labile enterotoxin subunit B-bovine serum albumin nanoparticles for improving tumor-targeted drug delivery via heat-labile enterotoxin subunit B mediation
L. Zhao (2014)
Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting.
A. Mitra (2006)
10.1371/journal.pone.0051960
Efficacy, Safety and Anticancer Activity of Protein Nanoparticle-Based Delivery of Doxorubicin through Intravenous Administration in Rats
Kishore Golla (2012)
Folate-functionalized polymeric micelles based on biodegradable PEG-PDLLA as a hepatic carcinoma-targeting delivery system.
Chuanqiang Niu (2011)
10.1016/j.jconrel.2009.09.010
Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives.
E. J. Oh (2010)
10.1021/bc9005656
Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release.
Shuyi Chen (2010)
10.1016/j.phrs.2013.01.009
cRGD-functionalized polymeric magnetic nanoparticles as a dual-drug delivery system for safe targeted cancer therapy.
J. Shen (2013)
Somatostatin and its receptor family. Front Neuroendocrinol
Y C Patel (1999)
10.1002/adma.201102313
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.
Forrest M Kievit (2011)
10.1016/j.surg.2014.04.055
Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Osama A Alsaied (2014)
10.1021/am5091462
Cell microenvironment-controlled antitumor drug releasing-nanomicelles for GLUT1-targeting hepatocellular carcinoma therapy.
Yubo Guo (2015)
10.1038/srep06538
Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway
Xiaoming Bai (2014)
10.1016/j.biomaterials.2011.11.082
An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy.
M. Liu (2012)
10.1016/j.aca.2015.05.027
A repeatable assembling and disassembling electrochemical aptamer cytosensor for ultrasensitive and highly selective detection of human liver cancer cells.
Duanping Sun (2015)
10.1021/acs.molpharmaceut.5b00879
Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles To Induce Autophagy-Mediated Liver Cancer Combination Therapy.
F. Wang (2016)
Structuredependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator–activated receptor γ agonists in colon cancer cells
S Chintharlapalli (2007)
10.1016/J.JCONREL.2006.06.014
Polymeric conjugates of mono- and bi-cyclic αvβ3 binding peptides for tumor targeting
A. Mitra (2006)
10.1079/BJN2002763
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.
I. Wood (2003)
Selfassembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system
K Na (2003)
10.1016/j.biomaterials.2010.11.010
PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo.
K. Choi (2011)
Overexpression of retinoic acid receptor alpha in hepatocellular carcinoma.
K. Sano (2003)
10.1016/J.JHEP.2004.09.006
Angiogenesis and hepatocellular carcinoma.
D. Semela (2004)
10.2147/IJN.S57744
Folate-targeted paclitaxel-conjugated polymeric micelles inhibits pulmonary metastatic hepatoma in experimental murine H22 metastasis models
Y. Zhang (2014)
10.1111/j.1549-8719.2009.00004.x
Liver Sinusoidal Endothelial Fenestrations in Caveolin‐1 Knockout Mice
A. Warren (2010)
10.1073/PNAS.85.19.7109
Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro.
S. Hardy (1988)
10.1021/JF0354848
HPLC-MSn analysis of phenolic compounds and purine alkaloids in green and black tea.
D. Del Rio (2004)
10.1186/s12876-015-0371-6
Decreased PCSK9 expression in human hepatocellular carcinoma
M. Bhat (2015)
10.1016/j.ijpharm.2012.10.030
Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
L. Zhang (2013)
10.1016/S0168-3659(00)00368-0
Evidence for receptor-mediated hepatic uptake of pullulan in rats.
Y. Kaneo (2001)
10.1021/mp3002733
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.
F. Danhier (2012)



This paper is referenced by
10.3389/fbioe.2020.00512
Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA
Q. Zheng (2020)
10.1039/C8TB02946F
Non-viral nanocarriers for intracellular delivery of microRNA therapeutics.
Zhiman Bai (2019)
10.1002/adma.201904329
Advanced Nanotechnology Leading the Way to Multimodal Imaging-Guided Precision Surgical Therapy.
C. Wang (2019)
10.1007/s10989-019-09901-8
Bioinformatics Predictions, Expression, Purification and Structural Analysis of the PE38KDEL-scfv Immunotoxin Against EPHA2 Receptor
E. Rezaie (2019)
10.1039/C7RA08796A
Surface decoration of selenium nanoparticles with curcumin induced HepG2 cell apoptosis through ROS mediated p53 and AKT signaling pathways
M. Guo (2017)
10.1016/j.cej.2020.124630
Natural plant-derived polygalacturonic acid-oleanolic acid assemblies as oral-delivered nanomedicine for insulin resistance treatment
Yuanjin Zhang (2020)
10.1016/j.ijbiomac.2020.12.019
Comparative study of two poly(amino acid)-based photosensitizer-delivery systems for photodynamic therapy.
Y. Bao (2020)
10.1080/17425247.2021.1860939
Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine.
V. Kumar (2020)
10.1080/08982104.2020.1768111
Retinal Photoreceptors Targeting SA-g-AA Coated Multilamellar Liposomes Carrier System for Cytotoxicity and Cellular Uptake Evaluation.
Anishiya Chella Daisy E R (2020)
10.2147/IJN.S134367
Preparation of a dual cored hepatoma-specific star glycopolymer nanogel via arm-first ATRP approach
Shaofeng Lou (2017)
10.1016/j.omtn.2020.01.034
Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes
Samrat Chakraborty (2020)
10.1155/2020/4638192
The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target
L. Baboci (2020)
10.2174/1389200220666191003161114
Recognition Sites for Cancer-Targeting Durg Delivery Systems.
Siyu Guan (2019)
10.1007/978-3-030-29168-6_12
Asialoglycoprotein Receptor and Targeting Strategies
S. Das (2019)
10.1021/acsnano.7b00312
One-Step Formulation of Targeted Aggregation-Induced Emission Dots for Image-Guided Photodynamic Therapy of Cholangiocarcinoma.
Min Li (2017)
10.3390/nu10080977
Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease
D. Uchida (2018)
10.21037/JGO.2020.02.10
Application of photodynamic therapy for liver malignancies.
Heng Zou (2020)
10.1016/j.ccr.2019.213076
AIE-based cancer theranostics
M. Gao (2020)
10.2147/IJN.S198848
Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles
N. Iturrioz-Rodríguez (2019)
10.1016/j.ejps.2019.104978
Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Lakshmi Tunki (2019)
10.4254/wjh.v9.i21.907
Chemotherapy for hepatocellular carcinoma: The present and the future
Marco Le Grazie (2017)
10.1016/J.CARBPOL.2019.04.041
Angelica sinensis polysaccharide nanoparticles as a targeted drug delivery system for enhanced therapy of liver cancer.
Y. Zhang (2019)
10.1039/c9tb02871d
Recent advances of nanomedicines for liver cancer therapy.
Xiaoqin Chi (2020)
10.1557/jmr.2020.95
Design, synthesis, and characterization of glycyrrhetinic acid-mediated multifunctional liver-targeting polymeric carrier materials
Qingxia Guan (2020)
10.3892/ol.2018.7988
Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression
Zirong Pan (2018)
10.1016/j.biopha.2020.110443
Fabrication of chlorambucil loaded graphene- oxide nanocarrier and its application for improved antitumor activity.
G. Singh (2020)
DEVELOPMENT OF INNOVATIVE FORMULATIONS BASED ON POLYSACCHARIDES FOR TUMOR TREATMENT
Simona Giarra (2017)
10.1002/hep.29643
Targeted delivery of microRNA‐199a‐3p using self‐assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice
Aditi Varshney (2018)
10.1208/s12249-020-1629-z
A Comparative Investigation of the Ability of Various Aptamer-Functionalized Drug Nanocarriers to Induce Selective Apoptosis in Neoplastic Hepatocytes: In Vitro and In Vivo Outcome
Samrat Chakraborty (2020)
10.7150/thno.29101
Theranostic Nanodots with Aggregation-Induced Emission Characteristic for Targeted and Image-Guided Photodynamic Therapy of Hepatocellular Carcinoma
Y. Gao (2019)
10.3892/ol.2018.8994
VTIQ evaluates antitumor effects of NET-1 siRNA by UTMD in HCC xenograft models
Xitian Liang (2018)
10.1016/j.msec.2018.02.006
Advances in thermosensitive polymer-grafted platforms for biomedical applications.
P. Le (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar